Related Experiment Video
Updated: Jan 15, 2026

06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.3K
Humanized Mouse Models for Type 1 Diabetes
David V Serreze1, Marissa Tousey-Pfarrer1, Jeremy J Racine1
1The Jackson Laboratory, Bar Harbor, Maine.
Current Protocols
|October 13, 2025
Summary
Humanizing NOD mice with patient-specific HLA and T cell receptors using CRISPR/Cas9 creates better models for type 1 diabetes (T1D) research. This approach advances the development of effective T1D interventions.
Area of Science:
- Immunology
- Genetics
- Endocrinology
Background:
- Type 1 diabetes (T1D) is an autoimmune disease primarily driven by T cells and influenced by polygenic factors.
- Major histocompatibility complex (MHC) and human leukocyte antigen (HLA) variants are key genetic risk factors for T1D.
- Current NOD mouse models offer insights but have limitations in translating findings to human T1D.
Purpose of the Study:
- To review the development and application of humanized NOD mouse models for T1D research.
- To explore the use of CRISPR/Cas9 technology in creating these advanced preclinical models.
- To highlight the potential of these models for identifying clinically relevant T1D intervention strategies.
Main Methods:
- Utilizing CRISPR/Cas9 gene editing to generate NOD mice deficient in murine MHC.
- Introducing human HLA and T cell receptor (TCR) molecules into these modified mice.
- Characterizing the resulting humanized mouse models for their T1D pathogenesis.
Main Results:
- CRISPR/Cas9 enables the creation of murine-MHC-deficient NOD mice.
- These mice can be engineered to express patient-relevant HLA and TCR molecules.
- The humanized models better recapitulate human T1D development, offering improved platforms for study.
Conclusions:
- Humanized NOD mice represent a significant advancement in preclinical T1D research.
- These models facilitate the development and testing of novel, clinically translatable T1D interventions.
- This approach holds promise for advancing treatments for T1D and other autoimmune diseases.

